We found that METTL3 mediates the m6A modification of AKT1‐mRNA, leading to increased AKT1‐mRNA and protein expression, which renders MSCs more likely to differentiate into adipocytes, thus changing the BMM and causing changes in AML chemoresistance (Fig. 6). Here, METTL3 is linked to acute myeloid leukemia.